MOGRIFY
LIVE

Serial Number

79289697

Owner

Mogrify Limited

Attorney

Rebecca Liebowitz

Filing Date

May 13, 2020

Add to watchlist:

No watchlists yet
View on USPTO

MOGRIFY Trademark

Serial Number: 79289697 • Registration: 6430514

MOGRIFY is a trademark filed by Mogrify Limited on May 13, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Mogrify Limited (2 trademarks)

25 Cambridge Science Park,

Entity Type: 99

Trademark Details

Filing Date

May 13, 2020

Registration Date

July 27, 2021

Published for Opposition

May 11, 2021

Goods & Services

Treatment and processing of biological materials, namely cells, stem cells, induced pluripotent stem cells; custom manufacture of therapeutic drugs, namely custom manufacture of transcription factors, cells and cell therapies, gene therapies ; information, advisory and consultancy services in relation to all of the aforesaid services

Downloadable bioinformatics software for genomic data analysis; downloadable computer software platforms for genomic data analysis in the fields of ophthalmology, haematology, immunology, neurology, respiratory diseases, metabolic conditions, genetic conditions, oncology, immuno-oncology, infectious diseases and cardiovascular diseases; scientific apparatus for measuring and analysing scientific study data in the nature of apparatus for recording, transmission or reproduction of data including video, audio, images and text; data analysis apparatus in the nature of data processing equipment and computers and downloadable operating computer software sold as a unit; downloadable scientific data analysis software

Medical and veterinary preparations for therapeutic purposes, namely pharmaceutical and biopharmaceutical preparations for the treatment of ophthalmological conditions, hematologic diseases, immune response disorders, neurological disorders, respiratory diseases, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; pharmaceutical and biopharmaceutical preparations for cell therapy; pharmaceutical and biopharmaceutical preparations for modifying human or animal cells for medical or therapeutic purposes; biological, chemical and biochemical reagents for medical use

Reagents for research purposes; molecular biology research tools in the nature of biological, chemical and biochemical reagents for research use

Medical services; veterinary services; medical services for the treatment of conditions of the human or animal body; medical services in the nature of manipulation of human and animal cells for therapeutic purposes; providing advice and consultancy in the field of medical and veterinary therapies

Scientific and technological services, namely, research and design in the fields of ophthalmology, haematology, immunology, neurology, respiratory diseases, metabolic conditions, genetic conditions, oncology, immuno-oncology, infectious diseases and cardiovascular diseases; industrial research services in the field of cell therapies and gene therapies; medical and veterinary research services in the nature of the manipulation of cells within a laboratory or research facility to enable the cells to be used for medical or therapeutic purposes; scientific research in human and animal cell therapy; scientific research into preparations for manipulating and adapting human and animal cells; design and development of new products for others; scientific laboratory services; software as a service (SaaS) services featuring software for use in genomic data analysis; platform as a service (Paas) services that feature a computer bioinformatics platform for use in manufacturing therapeutics; providing a bioinformatics platform for identifying transcription factors to turn one cell type into another cell type; advisory and consultancy relating to all the aforesaid services

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 4, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Dec 13, 2021 FICS
FINAL DISPOSITION PROCESSED
Dec 13, 2021 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 27, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Jul 27, 2021 R.PR
NOTIFICATION PROCESSED BY IB
May 11, 2021 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 11, 2021 NPUB
PUBLISHED FOR OPPOSITION
May 11, 2021 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 21, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 21, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 21, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 2, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Apr 2, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 2, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 2, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 2, 2021 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 25, 2021 GNFN
FINAL REFUSAL E-MAILED
Mar 25, 2021 GNFR
FINAL REFUSAL WRITTEN
Mar 25, 2021 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 4, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 4, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 4, 2021 TROA
REFUSAL PROCESSED BY IB
Oct 4, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 11, 2020 RFCS
REFUSAL PROCESSED BY MPU
Sep 11, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 12, 2020 RFCR
NON-FINAL ACTION WRITTEN
Aug 11, 2020 CNRT
ASSIGNED TO EXAMINER
Aug 10, 2020 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 25, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 21, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 16, 2020 REPR